YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
BridgeBio Pharma BBIO announced that the FDA accepted its regulatory filing seeking approval for the investigational oral drug infigratinib to treat children with achondroplasia, the most common form of dwarfism. The agency has granted the…
[Close up image of wooden cubes with alphabet Q3 on office desk.] mohd izzuan * BioMarin Pharmaceutical (BMRN [https://seekingalpha.com/symbol/BMRN]) said that it would incur an acquired in-process research and development (IPR&D) expense…
Ms. Bauer Brings More Than 25 Years of Experience in Human Resources, Across Biotechnology and Technology Industries Appointment Effective Oct. 5, 2026 SAN RAFAEL, Calif., Oct. 5, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq:…
[mrna Cancer Vaccine] wildpixel/iStock via Getty Images INVESTORS SHOULD KNOW: Personalized mRNA cancer vaccines are moving beyond their first major clinical success in melanoma into a broader test across harder-to-treat solid tumors. The…
Long-term data reinforce durable efficacy and safety of POMBILITI + OPFOLDA in late-onset Pompe disease SAN RAFAEL, Calif., Oct. 2, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new data evaluating the ef…
TCW Funds, an investment management firm, published its second-quarter 2026 investor letter for the "TCW Relative Value Mid Cap Fund". The letter can be downloaded here. Equities advanced in Q2 2026, with the S&P 500 reaching record highs…
Collaboration pairs Profluent's AI models with BioMarin's enzyme replacement therapy expertise to advance next-generation candidates for genetically defined conditions EMERYVILLE, Calif., September 30, 2026--(BUSINESS WIRE)--Profluent, the…
During these busy times, it pays to stay on top of the latest profit opportunities. And today's blog post should be a great place to start. After taking a close look at the latest data on institutional buying pressure and each company's fu…
3 Healthcare Stocks That Fall Short Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have benefited from elevated demand, and their mom…
Eric Dube, Ph.D., has decided to step down as President and Chief Executive Officer in December Following Eight Years of Exemplary Leadership Bradley L. Campbell to be Appointed President and CEO Effective December 1, 2026 SAN DIEGO, Septe…
BioMarin Pharmaceutical (BMRN) has been in focus after appointing Robert Plenge, M.D., Ph.D., to its Board and Science and Technology Committee, sharpening attention on how governance aligns with the rare-disease portfolio. Recent trading…
BioMarin Pharmaceutical recently reported positive Phase 3 CANOPY-HCH-3 results for VOXZOGO in children with hypochondroplasia and submitted a supplemental FDA application to expand the drug's use, while also adding Bristol Myers Squibb re…
Key Points Interested in BioMarin Pharmaceutical Inc.? Here are five stocks we like better. Amicus integration is advancing: BioMarin expects $200 million in annual non-GAAP cost savings, with most synergies realized in 2027 and full reali…
AstraZeneca AZN announced that the FDA accepted its regulatory filing seeking approval for its investigational enzyme replacement therapy (ERT) efzimfotase alfa to treat patients aged two years and older with hypophosphatasia (HPP). The FD…
BioMarin Pharmaceutical BMRN announced that it is discontinuing the development of Voxzogo (vosoritide) for children with Noonan syndrome, a rare genetic condition that can affect growth and development in multiple parts of the body. This…
3 Mid-Cap Stocks We Keep Off Our Radar Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe wit…
SAN RAFAEL, Calif., Sept. 14, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that the company has appointed Robert Plenge, M.D., Ph.D., to the company's Board of Directors, effective September 10, 2026.BioMarin…
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)'s stock rose 5% on August 31 after the company announced that it has entered into binding agreements with Ascendis Pharma A/S (NASDAQ:ASND) to resolve a global patent dispute over Ascendis's achon…
With products ranging from cardboard boxes to new drugs, these companies are all on track to double their earnings. Continue Reading
Detailed Phase 3 CANOPY-HCH-3 data in children living with hypochondroplasia also featured in a late-breaking oral presentation at the European Society for Paediatric Endocrinology (ESPE) 2026 Annual Meeting VOXZOGO demonstrated statistica…
Company Logo Opportunities center on earlier genetic diagnosis, targeted FGFR3 therapies, long-acting CNP analogs and oral inhibitors. Developers can improve access, affordability, adherence and lifelong complication management across the…
3 Reasons to Avoid BMRN and 1 Stock to Buy Instead BioMarin Pharmaceutical trades at $66.53 and has moved in lockstep with the market. Its shares have returned 9.3% over the last six months while the S&P 500 has gained 13.6%. Is there a bu…
3 Value Stocks We Think Twice About Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they're out of favor. The key risk, however, is that these stocks are us…
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has converted a global patent dispute with Ascendis Pharma A/S (NASDAQ:ASND) into a royalty-bearing license for Yuviwel, a once-weekly treatment approved to increase linear growth in children aged…
Ascendis Pharma (NasdaqGS:ASND) reached a global settlement and licensing agreement with BioMarin Pharmaceutical that resolves worldwide patent disputes related to Yuviwel. The deal grants Ascendis Pharma a license to continue commercializ…
For BioMarin Pharmaceutical BMRN, the FDA approval of Ascendis Pharma's ASND Yuviwel in February had created a problem — a new entrant targeting the same achondroplasia market as Voxzogo, its key revenue driver. But a recent settlement bet…
SAN DIEGO, September 03, 2026--(BUSINESS WIRE)--Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced the appointment of Barbara Bodem and Elizabeth Mily…
Vertex Pharmaceuticals logo By Midea Boston, Massachusetts-based Vertex Pharmaceuticals Incorporated (VRTX) develops and commercializes therapies for treating cystic fibrosis (CF). Valued at $139 billion by market cap, the company invests…
Wells Fargo 21st Annual Healthcare Conference, September 9 at 3:00 pm EST Cantor Global Healthcare Conference 2026, September 10 at 10:20 am EST Citi's 2026 Biopharma Back to School Conference, September 10 at 1:00 pm EST Morgan Stanley 24…
Rare diseases have moved steadily from being an overlooked corner of medicine to an important frontier for drug innovation. The FDA estimates that more than 7,000 rare diseases affect more than 30 million Americans, while most of these con…
Acquisition adds ALE1, a potential first oral therapy for hypophosphatasia to clinical pipeline SAN RAFAEL, Calif., Sept. 1, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) said today that it completed the previously annou…
On Sunday, BioMarin Pharmaceutical Inc.(NASDAQ:BMRN) reached a binding settlement with Ascendis Pharma A/S(NASDAQ:ASND)to resolve all global patent disputes regarding the medication Yuviwel. Ascendis Pharma's Yuviwel (navepegritide, develo…
Ascendis Pharma COPENHAGEN, Denmark, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it has entered into a binding term sheet for a global settlement and license agreement with BioMarin Pharmaceutical I…
Agreement Resolves all Pending Patent-Related Proceedings Between BioMarin and Ascendis SAN RAFAEL, Calif., Aug. 30, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that it has entered into binding terms wi…
The Trump administration is expected to announce a series of drug pricing deals with several mid-size biotech companies as early as Monday, adding to similar agreements reached with Big Pharma since late last year, Bloomberg News reported…
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. BioMarin Pharmaceutical (NasdaqGS:BMRN) agreed to acquire Alesta Therapeutics for up to US$490 million to expand its rare di…